Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Auteur principal: | Hoque, Ismoth Ara |
---|---|
Autres auteurs: | Azam, Faruque |
Format: | Thèse |
Langue: | English |
Publié: |
Brac University
2024
|
Sujets: | |
Accès en ligne: | http://hdl.handle.net/10361/23164 |
Documents similaires
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
par: Paul, Pulock
Publié: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
par: Rahman, Tasnim
Publié: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
par: Karim, Samia Binte
Publié: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
par: Flora, Sanzida Alam
Publié: (2024) -
Molecules associated with the development of lung cancer
par: Rahman, Adree, et autres
Publié: (2023)